Painful Sex Due to Vaginal Dryness (Dyspareunia): Don't Ignore the Pain, Solutions Exist

"It's Not in Your Head" — Starting the Conversation

A patient in her late forties told one of our clinicians last year that she'd been avoiding her husband's touch for almost a year, not because anything had changed between them, but because she'd learned to flinch before sex even started. She'd assumed this was just what happens with age. It isn't — and it's treatable.

That conversation captures something we hear often at Dr. Dina Rezk Clinic: women quietly rearrange their marriages, their sleep, even their sense of self, around a symptom nobody told them was common or fixable. Painful sex from vaginal dryness has a name — dyspareunia — a physical cause, and a range of treatments with different strengths, timelines, and trade-offs. This article walks through why it happens, what actually helps, in what order, and when the pain is telling you something needs a doctor's look rather than a home remedy.

What's Actually Happening in the Tissue

Estrogen keeps the vaginal lining thick, elastic, and well-lubricated. When estrogen drops — during the menopause transition, while breastfeeding, on certain medications, or after some cancer treatments — the vaginal walls thin, blood flow drops, and natural lubrication decreases. Clinicians call this collection of changes genitourinary syndrome of menopause (GSM) when it happens around menopause, though the same tissue changes can occur for other estrogen-related reasons at younger ages.

Thinner, less elastic tissue tears more easily under the friction of intercourse. That produces the burning or "raw" sensation many women describe, and sometimes light spotting afterward. Some women also develop protective pelvic floor muscle tightening once the brain starts anticipating pain — which then makes the next attempt more uncomfortable, not less. It's a mechanical problem layered with a learned response, and both parts usually need addressing.

Among postmenopausal women who report GSM symptoms, dyspareunia shows up in roughly 80% — making it one of the most frequently reported symptoms in this population, alongside dryness itself (Cureus, 2020). Unlike some menopausal symptoms that ease with time, GSM-related dryness and pain tend to persist or worsen the longer someone goes without treatment — one study found 84% of women affected six years after menopause, versus 65% at the one-year mark.

It isn't only a menopause issue. Pooled data across postpartum studies estimate dyspareunia affects around 35% of women after childbirth, most commonly linked to breastfeeding-related estrogen suppression, perineal healing, and the general physical adjustment of the fourth trimester (systematic review, 2020). For most, this improves as hormones normalize or breastfeeding tapers — but "most" isn't "everyone," and there's no reason to simply wait it out for months if it's affecting you now.

A Practical Self-Care Ladder: What to Try, and in What Order

We tend to walk patients through this in stages rather than jumping straight to prescriptions, because the least invasive options genuinely help a large share of women.

Step 1 — During sex: a lubricant. A generous amount of water-based or silicone-based lubricant, applied right before and reapplied during intercourse, reduces friction immediately. This is the fastest fix available and it's reasonable to start here regardless of the underlying cause. Avoid products with glycerin, added fragrance, or "warming/cooling" ingredients if your tissue is already irritated — plain formulas tend to be better tolerated. Non-hormonal lubricants and moisturizers are considered a first-line, evidence-supported option for urogenital dryness symptoms, including for women who cannot or prefer not to use hormonal treatment.

Step 2 — Between sex: a regular moisturizer. Lubricants solve the moment; they don't rebuild tissue. A vaginal moisturizer used two to three times a week, independent of when you're intimate, maintains hydration and comfort day to day, and several products (including hyaluronic-acid-based options) have shown meaningful improvement in comparative trials. Give this combination a genuine trial — most women who respond notice less friction within one to two weeks, though tissue quality itself takes longer, often four to eight weeks of consistent use, to meaningfully improve.

Step 3 — If that's not enough: talk to a doctor about estrogen or DHEA. When lubricants and moisturizers don't resolve the pain, particularly if dryness is due to menopause, low-dose vaginal estrogen (cream, tablet, or ring) or vaginal DHEA (prasterone) are the next step, prescribed and monitored by a clinician. These treat the tissue itself rather than just the friction.

This ladder isn't a rule that must be climbed in strict order for everyone. A woman with significant tissue thinning and a clear menopausal cause may reasonably move to step 3 sooner, in consultation with her doctor. But for most women, starting simple and escalating only if needed avoids unnecessary hormone exposure and often works.

Vaginal Estrogen and DHEA: What the Evidence Actually Shows

Low-dose vaginal estrogen remains the most established hormonal treatment for dryness-related dyspareunia tied to declining estrogen, and it works by restoring thickness, elasticity, and blood flow to the vaginal lining rather than just lubricating the surface. It's worth being precise about the evidence, though: a 2024 systematic review in the Annals of Internal Medicine concluded that vaginal estrogen, vaginal DHEA, oral ospemifene, and vaginal moisturizers "may all improve at least some GSM symptoms," but that their effect compared with placebo is modest in magnitude — not the dramatic, universal transformation some patient education material implies (Annals of Internal Medicine, 2024). We think that honesty matters: estrogen helps a meaningful number of women meaningfully, but it isn't a guarantee, and response varies.

Vaginal DHEA (prasterone, brand name Intrarosa) deserves specific mention here because it's the only therapy in this category with an FDA approval specifically tied to painful sex: it's approved for moderate-to-severe dyspareunia due to menopause, based on two 12-week placebo-controlled trials involving over 400 women (P&T, 2017). It's a once-daily vaginal insert; the body converts the hormone locally rather than through a systemic dose. As with vaginal estrogen, expect gradual improvement over weeks, not overnight relief, and discuss the specific product and regimen with your physician rather than self-selecting a dose.

Vaginal estrogen has minimal systemic absorption at the low doses used for local symptoms, and observational data, including from the Women's Health Initiative, have not found increased breast cancer risk with vaginal estrogen use in healthy postmenopausal women (Post Reprod Health, 2023). For women with a history of breast cancer, though, the approach is more individualized: non-hormonal options are tried first, and if vaginal estrogen becomes necessary, it's generally considered reassuring alongside tamoxifen but requires oncology input if the patient is on an aromatase inhibitor, where data on recurrence risk is more mixed (JNCI, 2022). This is a decision to make with both your gynecologist and your oncologist, not from an article.

We'd also flag pelvic floor physical therapy as an underused option when spasm — not just tissue thinning — is driving the pain. If your body has learned to brace in anticipation of discomfort, treating the tissue alone may not fully resolve things; a therapist trained in pelvic floor work can teach relaxation and desensitization techniques that address that learned guarding directly.

A Realistic Timeline, Not a Promise

Patients often ask, understandably, "how long until this stops hurting?" There's no single answer, but here's a reasonable general pattern based on what we see in clinic and what trial data suggest:

• Days 1–7: Lubricant use during intercourse typically reduces friction-related pain right away, though it won't address deeper tissue fragility if that's present.
• 1–3 weeks: Regular moisturizer use tends to improve day-to-day comfort and tissue suppleness; some women notice a meaningful difference here alone.
• 4–8 weeks: If vaginal estrogen or DHEA is started, this is the typical window in which most measurable tissue improvement occurs in clinical trials — gradual, not immediate.
• Ongoing: Maintenance use (of moisturizer or hormonal therapy) is usually needed to sustain improvement, since GSM-related changes don't resolve permanently on their own.

If you're several weeks into consistent use of any of these and notice no change at all, that's useful information for your doctor — it may mean a different formulation, an additional cause (such as a skin condition, infection, or pelvic floor spasm), or a different treatment altogether.

A Word on Privacy and Talking About This in Riyadh

We know that for many women in Riyadh and across the Gulf, even naming this problem out loud — to a doctor, let alone a partner — carries a layer of hesitation that isn't really about the symptom itself. Conversations about intimacy are private here in ways that are entirely reasonable, and we're not asking anyone to change that. What we do see, often, is women who waited years longer than they needed to because they assumed no one could discuss this comfortably or confidentially.

A few things help in practice: many patients find it easier to first describe the physical symptom (dryness, burning, spotting) rather than framing the visit around sexual difficulty — both routes lead to the same evaluation and treatment options. Appointments are conducted privately, and what's discussed stays between you and your clinician.

A Composite Patient Scenario

To make this concrete: a woman in her early fifties, two years post-menopause, came to clinic describing pain "like sandpaper" during intercourse that had been present for about eight months. She'd tried an over-the-counter lubricant with limited success and had started avoiding intimacy with her husband, which was creating tension neither of them wanted. On examination, her vaginal tissue showed clear signs of thinning consistent with GSM, with no bleeding, unusual discharge, or other red flags. She started a fragrance-free silicone lubricant for intercourse and a regular vaginal moisturizer three times weekly. After a follow-up at six weeks with partial but incomplete improvement, she and her physician discussed starting low-dose vaginal estrogen; by three months, she reported the pain was largely resolved and intimacy felt "normal again." (This is a composite drawn from common clinical patterns, not a specific patient record.)

Not every case follows this exact path — some women respond fully to the non-hormonal steps alone, others need DHEA instead of estrogen, and some need pelvic floor therapy layered in. The point isn't that this is the template; it's that steady, staged treatment usually gets somewhere, even when the first step isn't enough on its own.

Frequently Asked Questions

Contact Dr. Dina Rezk Clinic

If pain during intimacy has been part of your life for weeks or months, it's worth a conversation rather than continued avoidance. We handle these visits with full confidentiality, and treatment is tailored to your specific findings and history — not a one-size-fits-all prescription.

This article is for informational purposes only and does not substitute for professional medical evaluation. It cannot determine the cause of an individual patient's symptoms; a clinical examination may be needed for an accurate diagnosis and treatment plan.

References

1. The Menopause Society (NAMS). The 2020 genitourinary syndrome of menopause position statement. Menopause, 27(9), 976-992. Full text
2. ACOG Clinical Consensus (2021). Treatment of Urogenital Symptoms in Individuals With a History of Estrogen-Dependent Breast Cancer. Full text
3. Genitourinary syndrome of menopause overview. Cureus. 2020. Full text
4. Hormonal Treatments and Vaginal Moisturizers for GSM: Systematic Review. Annals of Internal Medicine. 2024. Full text
5. Randomized pilot trial — vaginal hyaluronic acid vs vaginal estrogen. Menopause. 2024. Full text
6. Vaginal estrogen safety review including Women's Health Initiative data. Post Reproductive Health. 2023. Full text
7. Systemic or Vaginal Hormone Therapy After Early Breast Cancer. JNCI. 2022. Full text
8. FDA approval of Intrarosa (prasterone/DHEA). Pharmacy and Therapeutics. 2017. Full text
9. Postpartum dyspareunia systematic review. 2020. Full text